Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: A path to potential...

Area of Science:

• Rheumatology
• Cardiology
• Immunology

Background:

• Systemic lupus erythematosus (SLE) patients have a significantly increased risk of cardiovascular disease (CVD).
• CVD is a leading cause of morbidity and mortality in SLE, especially with improved management of other disease manifestations.
• Immune system components are implicated in the development of atherosclerosis and endothelial damage in SLE.

Purpose of the Study:

• To review the clinical presentation of CVD in SLE patients.
• To explore the role of autoimmune responses in SLE-related atherogenesis, endothelial dysfunction, and cardiac disease.
• To discuss immune mediators as potential early CVD biomarkers and therapeutic targets in SLE.

Main Methods:

• Literature review of studies on cardiovascular disease in Systemic Lupus Erythematosus.
• Analysis of the role of immune constituents in SLE-associated cardiovascular pathology.
• Evaluation of immune mediators as potential biomarkers and therapeutic targets.

Main Results:

• Autoimmune responses, including specific cells, autoantibodies, and inflammatory mediators, are key drivers of CVD in SLE.
• These immune factors contribute to the induction of atherogenesis and endothelial impairment.
• Immune mediators show potential for early CVD detection and targeted interventions in SLE.

Conclusions:

• Cardiovascular disease is a critical complication of SLE, driven by underlying autoimmune processes.
• Understanding the role of immune mediators is crucial for developing novel diagnostic and therapeutic strategies for CVD in SLE.
• Targeting immune pathways may reduce cardiovascular morbidity and mortality in SLE patients.